Incidence of radiation proctitis in cervical cancer receiving radiation therapy at Dr. Kariadi Hospital, Semarang, Indonesia
Downloads
HIGHLIGHTS
- Radiation proctitis is a post-radiotherapy concern, urging research to reduce its occurrence and improve the well-being of patients.
- Radiotherapy is the primary treatment for advanced cervical cancer, offering hope and preserving quality of life for patients.
ABSTRACT
Objective: To determine the incidence of radiation proctitis in cervical cancer patients after radiation at Dr. Kariadi Hospital, Semarang, Indonesia.
Materials and Methods: A descriptive analytic study on 356 cervical cancer patients who received radiation therapy at Dr. Kariadi Hospital Semarang from January 2017 to December 2018 who met the inclusion criteria. Factors assessed included age, BMI, hematologic, stage, histopathology, history of radical hysterectomy surgery and duration of radiation. Cervical cancer staging was assessed using FIGO 2018. Statistical analysis was performed using Mann Whitney with a significant value of p <0.05.
Results: From the Chi-square analysis, the relationship between radiation period (less than 56 days and more than 56 days) (p=0.164), the relationship between age ≥45 and the incidence of proctitis (p=0.208), BMI ≥25 and the incidence of proctitis (p=0.838), Hb <10 with the incidence of proctitis (p=0.492), parity ≤1 with the incidence of proctitis (p=0.137), the relationship between the histopathological examination results with the incidence of proctitis (p=0.253), and stage level with the incidence of proctitis (p=0.226) were not significant. The highest incidence of proctitis occurred in stage 3B of the cervical cancer patients (14.5%).
Conclusion: The prevalence of proctitis in cervical cancer patients for the period 2017-2018 was 15.4%. Age, histopathological appearance, stage, history of anemia, history of radical surgery and appearance of symptoms after surgery with symptoms of proctitis did not show a significant relationship.
1. Chino J, Annunziata CM, Beriwal S, et al. Radiation therapy for cervical cancer: Executive summary of an ASTRO clinical practice guideline. Pract Radiat Oncol. 2020;10(4):220-34. doi: 10.1016/j.prro.2020.04.002. Epub 2020 May 18. PMID: 32473857; PMCID: PMC8802172.
Mahmoud O, Kilic S, Khan AJ, et al. External beam techniques to boost cervical cancer when brachytherapy is not an option-theories and applications. Ann Transl Med. 2017;5(10):207. doi: 10.21037/atm.2017.03.102. PMID: 28603722; PMCID: PMC5451624.
He Y, Zhao Q, Geng YN, et al. Analysis of short-term efficacy as defined by RECIST and pathological response of neoadjuvant chemotherapy comprised paclitaxel and cisplatin followed by radical surgery in patients with locally advanced cervical cancer: A prospective observational study. Medicine (Baltimore). 2018;97(22):e10913. doi: 10.1097/MD.0000000000010913. PMID: 298518 21; PMCID: PMC6392635.
Prihantono, Rusli R, Christeven R, et al. Cancer incidence and mortality in a tertiary hospital in Indonesia: An 18-year data review. Ethiop J Health Sci. 2023;33(3):515-22. doi: 10.4314/ejhs.v33i3. 15. PMID: 37576162; PMCID: PMC1041 6343.
World Health Organization. Cervical cancer [Internet]. WHO. 2022 [cited 2023 Mar11]. Available from: https://www.who.int/news-room/fact-sheets/detail/cervical-cancer
HOGI. Pedoman Nasional Pelayanan Kedokteran Kanker Ginekologi [National Guidelines for Cervical Cancer Medical Services]. Jakarta; 2018.
Hoffman BL, Schorge JO, Bradshaw KD, et al. Williams Gynecology. 3hd edition. McGraw-Hill Education; 2016.
Dasari P, Vivekanandam S, Raghava KSA. Radiation for gynaecological malignancies. In: Radiotherapy. Puducherry: Intech Open Science; 2017.
Tan LT, Tanderup K, Kiristis C, et al. Image-guided Adaptive Radiotherapy in Cervical Cancer. Seminars in Radiation Oncology. 2019;29(3):284-98. doi: 10.1016/j.semradonc.2019.02.010.
Grodsky MB, Sidani SM. Radiation proctopathy. Clin Colon Rectal Surg. 2015;28(2):103-11. doi: 10.1055/s-0035-1547337. PMID: 26034407; PMCID: PMC4442718.
Joiner MC, van der Kogel AJ. Basic clinical radiobiology. 5th edition. Danvers; CRC Press. Taylor & Francis Group. 2019.
Bhatla N, Berek JS, Cuello Fredes M, et al. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet. 2019;145(1):129-35. doi: 10.1002/ijgo.12749. Epub 2019 Jan 17. Erratum in: Int J Gynaecol Obstet. 2019;147(2):279-80. PMID: 30656645.
R. Susworo HK. Radioterapi, dasar-dasar radioterapi, tata laksana radioterapi penyakit kanker [Radiotherapy, basic radiotherapy, radiotherapy management for cancer]. Jakarta: UI Press; 2017.
Castela J, Mí£o de Ferro S, Ferreira S, et al. Management of severe radiation proctitis with radiofrequency ablation. GE Port J Gastroenterol. 2019;26(2):128-30. doi: 10.1159/000487447. Epub 2018 Mar 22. PMID: 30976619; PMCID: PMC6454389.
Dalsania RM, Shah KP, Stotsky-Himelfarb E, et al. Management of long-term toxicity from pelvic radiation therapy. Am Soc Clin Oncol Educ Book. 2021;41:1-11. doi: 10.1200/EDBK_323525. PMID: 33793314.
Santoso WJ, Iskandar TM. Perbedaan respon terapi kemoradiasi dengan radiasi pada karsinoma serviks uteri stadium IIB – IIIB [Difference in therapy response between chemoradiation and radiation in cervical carcinoma stage IIB -IIIB]. Semarang: Perpustakaan Fakultas Kedokteran Universitas Diponegoro; 2018.
Pui WC, Chieng TH, Siow SL, et al. A randomized controlled trial of novel treatment for hemorrhagic radiation proctitis. Asian Pac J Cancer Prev. 2020; 21(10):2927-34. doi: 10.31557/APJCP.2020.21.10. 2927. PMID: 33112550; PMCID: PMC779 8148.
Hong JC, Foote J, Broadwater G, et al. Total treatment duration for cervical cancer: Is 55 days still the goal in the era of concurrent chemo-therapy? Oral Scientific Session. 2016;96(2):S15. doi: 10.1016/j.ijrobp.2016.06.050.
Aghili M, Andalib B, Karimi Moghaddam Z, et al. Concurrent chemo-radiobrachytherapy with cisplatin and medium dose rate intra- cavitary brachytherapy for locally advanced uterine cervical cancer. Asian Pac J Cancer Prev. 2018;19(10): 2745-50. doi: 10.22034/APJCP.2018.19.10.2745. PMID: 30360600; PMCID: PMC6291044.
Huang EY, Lin H, Wang CJ, et al. Impact of treatment time-related factors on prognoses and radiation proctitis after definitive chemoradio-therapy for cervical cancer. Cancer Med. 2016; 5(9):2205-12. doi: 10.1002/cam4.794. Epub 2016 Jul 15. PMID: 27416796; PMCID: PMC5055176.
Tergas AI, Neugut AI, Chen L, et al. Radiation duration in women with cervical cancer treated with primary chemoradiation: A population-based analysis. Cancer Invest. 2016;34(3):137-47. doi: 10.3109/07357907.2015.1131291. Epub 2016 Mar 17. PMID: 26986809; PMCID: PMC4834975.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
1. Copyright of the article is transferred to the journal, by the knowledge of the author, whilst the moral right of the publication belongs to the author.
2. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution-Non Commercial-Share alike (CC BY-NC-SA), (https://creativecommons.org/licenses/by-nc-sa/4.0/)
3. The articles published in the journal are open access and can be used for non-commercial purposes. Other than the aims mentioned above, the editorial board is not responsible for copyright violation
The manuscript authentic and copyright statement submission can be downloaded ON THIS FORM.
